“…Specifically, patients with lung metastasis tend to experience a more favorable disease course compared to other sites of visceral metastasis [ 8 ]. As in Table 1 , prognosis and survival outcomes in prostate cancer lung metastasis vary significantly according to the present studies, with survival ranging from 3 to 88 months and a median survival of 26 months [ 13 , 15 , 17 , 18 , 20 , 21 , 23 , 24 , 25 , 28 , 29 , 35 , 36 , 37 , 38 , 41 , 44 , 45 , 46 , 47 , 49 , 52 , 54 , 55 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 69 , 71 ]. The survival outcomes depend on several factors, including the extent of metastatic spread, the aggressiveness of the disease, the presence of comorbidities, and the effectiveness of treatment interventions [ 93 ].…”